Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder Syndrome
Keywords: LOCF، آخرین مشاهدات به جلو رفت; urinary bladder; overactive; receptors; prostaglandin E; EP1 subtype; urination; urinary incontinence; urge; treatment outcomeATP, adenosine triphosphate; LOCF, last observation carried forward; OAB, overactive bladder; PG, prostaglandin; UUI, urgency uri